Cargando…
PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy
Ischemia-reperfusion injury (IRI) is a complex pathophysiological process that is often characterized as a blood circulation disorder caused due to various factors (such as traumatic shock, surgery, organ transplantation, burn, and thrombus). Severe metabolic dysregulation and tissue structure destr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117354/ https://www.ncbi.nlm.nih.gov/pubmed/33995008 http://dx.doi.org/10.3389/fphar.2021.600618 |
_version_ | 1783691576746180608 |
---|---|
author | Huang, Ruizhen Zhang, Chiyu Wang, Xing Hu, Honglin |
author_facet | Huang, Ruizhen Zhang, Chiyu Wang, Xing Hu, Honglin |
author_sort | Huang, Ruizhen |
collection | PubMed |
description | Ischemia-reperfusion injury (IRI) is a complex pathophysiological process that is often characterized as a blood circulation disorder caused due to various factors (such as traumatic shock, surgery, organ transplantation, burn, and thrombus). Severe metabolic dysregulation and tissue structure destruction are observed upon restoration of blood flow to the ischemic tissue. Theoretically, IRI can occur in various tissues and organs, including the kidney, liver, myocardium, and brain, among others. The advances made in research regarding restoring tissue perfusion in ischemic areas have been inadequate with regard to decreasing the mortality and infarct size associated with IRI. Hence, the clinical treatment of patients with severe IRI remains a thorny issue. Peroxisome proliferator-activated receptor γ (PPARγ) is a member of a superfamily of nuclear transcription factors activated by agonists and is a promising therapeutic target for ameliorating IRI. Therefore, this review focuses on the role of PPARγ in IRI. The protective effects of PPARγ, such as attenuating oxidative stress, inhibiting inflammatory responses, and antagonizing apoptosis, are described, envisaging certain therapeutic perspectives. |
format | Online Article Text |
id | pubmed-8117354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81173542021-05-14 PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy Huang, Ruizhen Zhang, Chiyu Wang, Xing Hu, Honglin Front Pharmacol Pharmacology Ischemia-reperfusion injury (IRI) is a complex pathophysiological process that is often characterized as a blood circulation disorder caused due to various factors (such as traumatic shock, surgery, organ transplantation, burn, and thrombus). Severe metabolic dysregulation and tissue structure destruction are observed upon restoration of blood flow to the ischemic tissue. Theoretically, IRI can occur in various tissues and organs, including the kidney, liver, myocardium, and brain, among others. The advances made in research regarding restoring tissue perfusion in ischemic areas have been inadequate with regard to decreasing the mortality and infarct size associated with IRI. Hence, the clinical treatment of patients with severe IRI remains a thorny issue. Peroxisome proliferator-activated receptor γ (PPARγ) is a member of a superfamily of nuclear transcription factors activated by agonists and is a promising therapeutic target for ameliorating IRI. Therefore, this review focuses on the role of PPARγ in IRI. The protective effects of PPARγ, such as attenuating oxidative stress, inhibiting inflammatory responses, and antagonizing apoptosis, are described, envisaging certain therapeutic perspectives. Frontiers Media S.A. 2021-04-28 /pmc/articles/PMC8117354/ /pubmed/33995008 http://dx.doi.org/10.3389/fphar.2021.600618 Text en Copyright © 2021 Huang, Zhang, Wang and Hu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Huang, Ruizhen Zhang, Chiyu Wang, Xing Hu, Honglin PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy |
title | PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy |
title_full | PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy |
title_fullStr | PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy |
title_full_unstemmed | PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy |
title_short | PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy |
title_sort | pparγ in ischemia-reperfusion injury: overview of the biology and therapy |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117354/ https://www.ncbi.nlm.nih.gov/pubmed/33995008 http://dx.doi.org/10.3389/fphar.2021.600618 |
work_keys_str_mv | AT huangruizhen pparginischemiareperfusioninjuryoverviewofthebiologyandtherapy AT zhangchiyu pparginischemiareperfusioninjuryoverviewofthebiologyandtherapy AT wangxing pparginischemiareperfusioninjuryoverviewofthebiologyandtherapy AT huhonglin pparginischemiareperfusioninjuryoverviewofthebiologyandtherapy |